Display Settings:

Format

Send to:

Choose Destination
    Alzheimers Res Ther. 2010 Jul 29;2(4):22.

    The role of animal models in advancing amyloid-beta immunotherapy to the clinic.

    Source

    Janssen Alzheimer Immunotherapy Research and Development, LLC, 700 Gateway, Blvd, South San Francisco, CA 94080, USA. Dora.Games@neotopebio.com.

    Abstract

    The amyloid-beta (Aβ) hypothesis of Alzheimer's disease (AD) causality is now well into its third decade and is finally entering a phase of rigorous clinical testing in numerous late stage clinical trials. The use of Aβ-based animal models of AD has been essential to the discovery and/or preclinical validation of many of these therapeutic approaches. While several neuropathologically based results from preclinical studies have translated nicely into AD patients, the full clinical value of Aβ-directed therapies awaits results from trials now in progress.

    PMID:
    20682084
    [PubMed]
    PMCID: PMC2949588
    Free PMC Article

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk